Can NKT cells extinguish smoldering myeloma?

Blood

Volumn 121, Issue 3, 2013, Pages 418-420

  Benson, Don M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD16 ANTIGEN; DEXAMETHASONE; LENALIDOMIDE; M PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSCRIPTION FACTOR SOX2;

ARTICLE; DENDRITIC CELL; DISEASE COURSE; EOSINOPHIL; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; IMMUNOTHERAPY; MONOCYTE; MULTIPLE MYELOMA; MYELOMA; NATURAL KILLER CELL; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOPATHY; T LYMPHOCYTE;

EID: 84872521953     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-465849     Document Type: Article

References (10)

1. Richter J, Neparidze N, Zhang L, et al. Clinical regression and broad immune activation following combination therapy targeting humanNKTcells in myeloma. Blood. 2013;121(3):423-430.
2. Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res. 2011;17(6):1243-1252.
3. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producingNKTresponse induced with alpha-galactosylceraminde-loaded DCs. Nat Immunol. 2002;3(9):867-874.
4. Chang DH, Osman K, Connolly J, et al. Sustained expansion ofNKTcells and antigen-specificTcells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201(9):1503- 1517.
5. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary humanTlymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8-subset. J Exp Med. 1998; 187(11):1885-1892.
6. Godfrey J, BensonDMJr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012;53(9):1666-1676.
7. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killerTcells by lenalidomide: therapeutic implications. Blood. 2006; 108(2) 618-621.
8. Spisek R, Kukreja A, Chen LC, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med. 2007;204(4):831-840.
9. BensonDMJr, Bakan CE, Zhang S, Collins SM, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118(24):6387-6391.
10. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117(5):1605-1613.